195 related articles for article (PubMed ID: 30964293)
1. Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer.
Zhang Y; Wu X; Xue X; Li C; Wang J; Wang R; Zhang C; Wang C; Shi Y; Zou L; Li Q; Huang Z; Hao X; Loomes K; Wu D; Chen HW; Xu J; Xu Y
J Med Chem; 2019 May; 62(9):4716-4730. PubMed ID: 30964293
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Characterization of Benzimidazole Derivative XY123 as a Potent, Selective, and Orally Available RORγ Inverse Agonist.
Wu X; Shen H; Zhang Y; Wang C; Li Q; Zhang C; Zhuang X; Li C; Shi Y; Xing Y; Xiang Q; Xu J; Wu D; Liu J; Xu Y
J Med Chem; 2021 Jun; 64(12):8775-8797. PubMed ID: 34121397
[TBL] [Abstract][Full Text] [Related]
3. Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.
Song Y; Xue X; Wu X; Wang R; Xing Y; Yan W; Zhou Y; Qian CN; Zhang Y; Xu Y
Eur J Med Chem; 2016 Jun; 116():13-26. PubMed ID: 27043267
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
[TBL] [Abstract][Full Text] [Related]
5. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
Zhang M; Zhang Y; Song M; Xue X; Wang J; Wang C; Zhang C; Li C; Xiang Q; Zou L; Wu X; Wu C; Dong B; Xue W; Zhou Y; Chen H; Wu D; Ding K; Xu Y
J Med Chem; 2018 Apr; 61(7):3037-3058. PubMed ID: 29566488
[TBL] [Abstract][Full Text] [Related]
6. Discovery of biaryls as RORγ inverse agonists by using structure-based design.
Enyedy IJ; Powell NA; Caravella J; van Vloten K; Chao J; Banerjee D; Marcotte D; Silvian L; McKenzie A; Hong VS; Fontenot JD
Bioorg Med Chem Lett; 2016 May; 26(10):2459-2463. PubMed ID: 27080181
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity.
Lu B; Liu D; Gui B; Gou J; Dong H; Hu Q; Feng J; Mao Y; Shen X; Wang S; Zhang C; Shen R; Yan Y; Chen L; Wang H; Li D; Zhang J; Zhang M; Zhang R; Bai C; He F; Tao W; Liu S
J Med Chem; 2021 Oct; 64(20):14983-14996. PubMed ID: 34643383
[TBL] [Abstract][Full Text] [Related]
8. Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Chao J; Enyedy I; Van Vloten K; Marcotte D; Guertin K; Hutchings R; Powell N; Jones H; Bohnert T; Peng CC; Silvian L; Hong VS; Little K; Banerjee D; Peng L; Taveras A; Viney JL; Fontenot J
Bioorg Med Chem Lett; 2015 Aug; 25(15):2991-7. PubMed ID: 26048806
[TBL] [Abstract][Full Text] [Related]
9. Discovery of phenoxyindazoles and phenylthioindazoles as RORγ inverse agonists.
Ouvry G; Bouix-Peter C; Ciesielski F; Chantalat L; Christin O; Comino C; Duvert D; Feret C; Harris CS; Lamy L; Luzy AP; Musicki B; Orfila D; Pascau J; Parnet V; Perrin A; Pierre R; Polge G; Raffin C; Rival Y; Taquet N; Thoreau E; Hennequin LF
Bioorg Med Chem Lett; 2016 Dec; 26(23):5802-5808. PubMed ID: 27815118
[TBL] [Abstract][Full Text] [Related]
10. A reversed sulfonamide series of selective RORc inverse agonists.
van Niel MB; Fauber BP; Cartwright M; Gaines S; Killen JC; René O; Ward SI; de Leon Boenig G; Deng Y; Eidenschenk C; Everett C; Gancia E; Ganguli A; Gobbi A; Hawkins J; Johnson AR; Kiefer JR; La H; Lockey P; Norman M; Ouyang W; Qin A; Wakes N; Waszkowycz B; Wong H
Bioorg Med Chem Lett; 2014 Dec; 24(24):5769-5776. PubMed ID: 25453817
[TBL] [Abstract][Full Text] [Related]
11. Structural determinant for inducing RORgamma specific inverse agonism triggered by a synthetic benzoxazinone ligand.
Marcotte DJ; Liu Y; Little K; Jones JH; Powell NA; Wildes CP; Silvian LF; Chodaparambil JV
BMC Struct Biol; 2016 Jun; 16(1):7. PubMed ID: 27246200
[TBL] [Abstract][Full Text] [Related]
12. Discovery and Optimization of a Series of Sulfonamide Inverse Agonists for the Retinoic Acid Receptor-Related Orphan Receptor-α.
Doebelin C; He Y; Campbell S; Nuhant P; Kumar N; Koenig M; Garcia-Ordonez R; Chang MR; Roush WR; Lin L; Kahn S; Cameron MD; Griffin PR; Solt LA; Kamenecka TM
Med Chem; 2019; 15(6):676-684. PubMed ID: 30799793
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer.
Xiang Q; Wang C; Zhang Y; Xue X; Song M; Zhang C; Li C; Wu C; Li K; Hui X; Zhou Y; Smaill JB; Patterson AV; Wu D; Ding K; Xu Y
Eur J Med Chem; 2018 Mar; 147():238-252. PubMed ID: 29448139
[TBL] [Abstract][Full Text] [Related]
14. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis.
Ouvry G; Atrux-Tallau N; Bihl F; Bondu A; Bouix-Peter C; Carlavan I; Christin O; Cuadrado MJ; Defoin-Platel C; Deret S; Duvert D; Feret C; Forissier M; Fournier JF; Froude D; Hacini-Rachinel F; Harris CS; Hervouet C; Huguet H; Lafitte G; Luzy AP; Musicki B; Orfila D; Ozello B; Pascau C; Pascau J; Parnet V; Peluchon G; Pierre R; Piwnica D; Raffin C; Rossio P; Spiesse D; Taquet N; Thoreau E; Vatinel R; Vial E; Hennequin LF
ChemMedChem; 2018 Feb; 13(4):321-337. PubMed ID: 29327456
[TBL] [Abstract][Full Text] [Related]
15. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
16. Discovery of the First-in-Class RORγ Covalent Inhibitors for Treatment of Castration-Resistant Prostate Cancer.
Fang W; Zheng J; Deng L; An Y; Rong D; Wei J; Xiong XF; Wang J; Wang Y
J Med Chem; 2024 Jan; 67(2):1481-1499. PubMed ID: 38227771
[TBL] [Abstract][Full Text] [Related]
17. Ligand-Based Design of Allosteric Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists.
Meijer FA; Doveston RG; de Vries RMJM; Vos GM; Vos AAA; Leysen S; Scheepstra M; Ottmann C; Milroy LG; Brunsveld L
J Med Chem; 2020 Jan; 63(1):241-259. PubMed ID: 31821760
[TBL] [Abstract][Full Text] [Related]
18. New Therapeutic Target for Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc.
Fauber BP; de Leon Boenig G; Burton B; Eidenschenk C; Everett C; Gobbi A; Hymowitz SG; Johnson AR; Liimatta M; Lockey P; Norman M; Ouyang W; René O; Wong H
Bioorg Med Chem Lett; 2013 Dec; 23(24):6604-9. PubMed ID: 24239186
[TBL] [Abstract][Full Text] [Related]
20. Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.
Amaudrut J; Argiriadi MA; Barth M; Breinlinger EC; Bressac D; Broqua P; Calderwood DJ; Chatar M; Cusack KP; Gauld SB; Jacquet S; Kamath RV; Kort ME; Lepais V; Luccarini JM; Masson P; Montalbetti C; Mounier L; Potin D; Poupardin O; Rouaud S; Spitzer L; Wallace CD
Bioorg Med Chem Lett; 2019 Jul; 29(14):1799-1806. PubMed ID: 31101472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
